Where to buy SLU-PP-332 (ERR agonist, exercise mimetic) in the UK: the sellers with a verifiable COA
The newest verifiable SLU-PP-332 certificate on any UK seller's website is on Xlpeptides (xlpeptides.com), analysed 22 Aug 2025 (task #76137 on Janoshik's site); 1 verified seller holds one covering SLU-PP-332, listed newest first below. Of the 450 active UK sellers we audit, 38 (8%) publish their own verifiable Janoshik certificate of analysis, and this page lists which of them hold one covering SLU-PP-332, newest certificate first. It is a record of paperwork, not a recommendation: The Peptide Watch sells nothing, takes no money from sellers and links to none of them. SLU-PP-332 is a small molecule, not a peptide, made at Saint Louis University in 2023 as a pan-agonist of the estrogen-related receptors and described as an exercise mimetic in mice. It has ten papers, no human study and no registered trial. Purity and identity cannot be judged by eye, so an independent certificate you can check is the only real proof of what is in the vial.
The one test that matters for SLU-PP-332
Ignore the marketing. The question is simple: does the seller publish a verifiable Janoshik certificate that names the seller itself as the client? If it does, you can confirm an independent lab tested that batch. If it shows an in-house document, a borrowed certificate, or "COA on request", you cannot. Learn the two-minute check in how to verify a Janoshik COA.
Which UK sellers publish a verifiable COA
Of the 450 active UK research-peptide sellers we audit, only 38 (8%) publish their own verifiable Janoshik certificate. Any of them is where you can actually verify testing, for SLU-PP-332 or any compound. A few: Lab77Peptides · Peptology Labs · Biovanta · Camo Chem · Biohackpeptides · Zenic Labs. See the full independently-tested list, or check a specific shop's certificate with the free COA Checker.
Verified UK vendors with a confirmed SLU-PP-332 Janoshik certificate (1)
- Xlpeptides xlpeptides.com · newest SLU-PP-332 report 22 Aug 2025 · task #76137
Audit findings, not recommendations. Every entry is a report covering SLU-PP-332 that we opened on Janoshik's own site and that names the seller itself as the client; the date is the analysis date printed on the report where we have read it, otherwise the date the laboratory received the sample. The table below is the same ledger in full, so the two always agree. Not exhaustive: a vendor whose SLU-PP-332 report we have not yet read is not listed.
The one verifiable SLU-PP-332 certificate we have read
Each row was opened on Janoshik's own site by a real page load and transcribed. The client column is the name the laboratory printed; a certificate counts as a seller's own only when that name is the seller. The report date is the analysis date printed on the report where we have read it, otherwise the date the laboratory received the sample. The verify link opens the laboratory, never the shop. Audit findings, not recommendations.
| Seller | Task | Client on the report | Report date | Result | Batch | |
|---|---|---|---|---|---|---|
| Xlpeptides | #76137 | XL Peptides | 22 Aug 2025 | SLU-PP-332 · 172.83 mcg; 194.35 mcg | Unknown | verify |
What the one SLU-PP-332 certificate shows
We have read one Janoshik report covering SLU-PP-332, published by one UK seller. It was opened on Janoshik's own website and names the seller itself as the client. It is dated 22 Aug 2025.
A certificate is a batch document. The lines that matter are the compound (it must say SLU-PP-332, not only a batch code), the client (the shop, not its supplier) and the analysis date. A new batch is untested until a new report appears.
Questions people ask
Which UK sellers publish a verifiable Janoshik certificate naming SLU-PP-332?
As of 4 October 2026, one: Xlpeptides. It has a report on Janoshik's own website that names the seller as the client and lists SLU-PP-332. That is a statement about paperwork, not a recommendation; The Peptide Watch does not recommend anywhere to buy SLU-PP-332.
How recent is the newest SLU-PP-332 certificate from a UK seller?
The newest we have read is Janoshik task #76137, sample received 22 Aug 2025. It is published by Xlpeptides and names it as the client. A certificate covers one batch, so an old one says little about stock on sale today.
How do I check that a certificate for SLU-PP-332 is genuine?
Four things: an independent laboratory is named; the client field names the seller you are buying from, not a supplier; the compound line says SLU-PP-332; and the report's task number and key open the same report on the laboratory's own website (verify.janoshik.com). A branded PDF with no laboratory name and no verification code fails on the first check, however professional it looks. The free COA Checker on this site runs the checks for you.
Is SLU-PP-332 a licensed medicine in the UK?
Not a medicine anywhere. Sold as a research chemical. Preclinical: mouse studies only, no trial registered. The Peptide Watch does not give legal or medical advice.
Why does The Peptide Watch not say where to buy SLU-PP-332?
Because the site records paperwork, not recommendations. A verifiable certificate proves that a sample of one batch was tested. It does not prove the vial you receive matches it, and it says nothing about whether anyone should use SLU-PP-332. Listing which sellers publish a certificate you can check, and which publish nothing, is as far as the evidence goes.
SLU-PP-332 in the UK at a glance
| Active UK sellers listing SLU-PP-332 | 5 |
|---|---|
| Of which publish a verifiable own-name certificate | 1 |
| Of which name no laboratory at all | 2 |
| Paying for Google Ads on it | 0 |
| Sellers of it that have closed or vanished | 0 |
Counted from the vendor ledger at build time: a seller is included when its audit records SLU-PP-332 in its certificates or its catalogue notes. Audit findings, not recommendations.
The other 4 sellers: what they publish instead
- No named lab, nothing to verify: 2
- Hides behind an 'accredited UK lab': 1
- No testing claim found: 1
Each pattern is explained on the seller's own audit page, with what we saw and the date. The A-Z directory lists every seller.
The market for SLU-PP-332 in the UK
Companies. 1 of the 5 can be matched to a Companies House record; the median company is 2.7 years old and 0 were incorporated within the last year. A seller with no traceable company is not necessarily dishonest, but there is nobody to hold to its certificate.
Reviews. 1 of the 5 have a Trustpilot profile with a score; the median is 4.4, 0 sit at 4.5 or above and 0 below 3.0. A review score says who collects reviews, not who tests, which is why it sits next to a certificate and never instead of one.
Changes among SLU-PP-332 sellers
- 2026-09-23 Labs of London (labsoflondon.com) added to the audit on the watch list.
- 2026-09-16 Protynx Labs (protynxlabs.com) added to the audit on the watch list.
- 2026-09-15 Xlpeptides (xlpeptides.com) published a newer own-name certificate (now Apr 2026).
- 2026-08-30 MyPep Biotech (mypepbiotech.co.uk) added to the audit on the watch list.
From the site changelog, which also runs as a JSON feed.
What the research shows for SLU-PP-332, and what it does not
| Papers on PubMed | 10 |
|---|---|
| Indexed as rat or mouse studies | 5 |
| Indexed as clinical trials | 0 |
| Published since 2020 | 10 |
| Trials registered on ClinicalTrials.gov | 0 |
Ten papers, all since 2023, none in people. SLU-PP-332 is a small molecule, not a peptide, made in Thomas Burris's laboratory at Saint Louis University as a pan-agonist of the three estrogen-related receptors, the name being the university's initials. The first paper, in ACS Chemical Biology in 2023, reported that it triggered an exercise-like response in mouse muscle and raised treadmill endurance; later mouse studies covered obesity, heart failure and kidney ageing. PubMed indexes 10 papers; there is no human study and ClinicalTrials.gov lists none.
Where development stands. The patents belong to Saint Louis University. Burris has disclosed a stake in Pelagos Pharmaceuticals, which works on this receptor class, and his group has since published an orally active successor, SLU-PP-915, describing the original as lacking oral bioavailability. That is a sign that whatever reaches a trial will not be the compound sold online. Anti-doping laboratories published detection methods for it in 2026; it is not named on the 2026 WADA list.
What a certificate can tell you. One report, from XL Peptides in August 2025, measured 172.83 and 194.35 micrograms in two vials against a 200 microgram label, with no purity figure.
Who owns SLU-PP-332, and where it stands
| Originator | Thomas Burris and colleagues, Saint Louis University, 2023. |
|---|---|
| Rights | Saint Louis University patents; no licensee announced. |
| Development status | Preclinical. Preclinical: mouse studies only, no trial registered. |
| Clinical trials | 0 registered on ClinicalTrials.gov |
| In the UK | Not a medicine anywhere. Sold as a research chemical. |
Counts are from PubMed on 15 September 2026 using the queries recorded in our evidence file; "clinical trial" is PubMed's own publication-type index. This is a description of the published record, not medical advice and not an argument for or against use.
Sources (7)
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. (ACS Chem Biol, 2023, PMID 36988910)
- Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. (Am J Pathol, 2023, PMID 37717940)
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. (Circulation, 2024, PMID 37961903)
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. (J Pharmacol Exp Ther, 2026, PMID 41421047)
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. (Int J Biol Macromol, 2026, PMID 41850449)
- Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. (Drug Test Anal, 2026, PMID 41688415)
- Burris laboratory, 2026, orally active ERR agonist SLU-PP-915 (PubMed)
The Peptide Watch's position on SLU-PP-332
Not a medicine anywhere. Sold as a research chemical. The Peptide Watch reads the certificates UK sellers publish and does not recommend anywhere to buy SLU-PP-332. Sellers on this page are listed by the date of their newest SLU-PP-332 certificate and by nothing else. If you can verify a seller's testing, you can at least judge its evidence; if you cannot, you are taking the seller's word for what is in the vial. See how UK testing compares across every seller in the market statistics.
An honest note: a verifiable certificate proves a sample of a batch was tested, not that the specific vial you receive matches it, see what this can and can't tell you. The Peptide Watch sells no SLU-PP-332 and links to no shop; this is research-use-only information, not medical or dosing advice.
All peptides · Other compounds: BPC-157 · TB-500 · GHK-Cu · Ipamorelin · CJC-1295 · MOTS-c · Epithalon · Selank · Semax · Tesamorelin · Melanotan 2 · KPV · PT-141 · SS-31 · DSIP · NAD+ · Melanotan 1 · AOD-9604 · 5-Amino-1MQ · Glutathione · Kisspeptin · Thymosin Alpha-1 · GHRP-6 · HGH Fragment 176-191 · IGF-1 LR3 · FOXO4-DRI · Oxytocin · MK-677 · GLOW and KLOW blends · Sermorelin · GHRP-2 · Hexarelin · ARA-290 · AHK-Cu